The AGO Study Group (AGO-OVAR) is a non-profit organization founded in 1993 with the aim of improving the therapy for cancers of the female genital organs, in particular ovarian carcinoma. Originally, the group focused on researching and optimizing the treatment of ovarian cancer, but since 2007 it has expanded its range of activities to include other tumor diseases of the external and internal female genital organs such as the cervix and uterus[1].
As one of the most influential study groups in the field of gynecological oncology, AGO-OVAR works closely with over 250 medical institutions in Germany and with international partners to initiate and conduct clinical trials, promote medical training in the field and intensify professional exchange in national and international expert groups[1]. The focus is on innovative clinical research projects, which include studies on new therapy combinations and treatment methods for advanced or recurrent ovarian cancer, for example studies on immunotherapies (Atezolizumab), targeted agents or protein kinase inhibitors[2][5].
The corporate mission of AGO-OVAR is to sustainably improve the treatment success and quality of life of patients with gynecological cancers through scientifically sound research and cooperation. The organization attaches great importance to evidence-based medicine, critical evaluation of new therapies and the responsible use of innovative methods, such as hyperthermic intraperitoneal chemotherapy (HIPEC), the use of which outside controlled studies is classified as experimental by AGO-OVAR and critically monitored[3].
Sustainability is particularly evident in the long-term commitment to high-quality, patient-centered research that systematically contributes to expanding therapy options on an evidence-based basis and thus raising the standard of clinical care. The focus on interdisciplinary and international cooperation also promotes sustainable networking and the transfer of knowledge within the professional world. The study results should not only provide short-term scientific insights, but should be permanently incorporated into guidelines and everyday clinical practice in order to optimize the treatment of gynecological tumors worldwide[1][5].
In summary, the AGO Study Group is a leading, research-driven institution that promotes innovative therapies for cancers of the female genital organs through clinical trials, professional networking and ongoing scientific evaluation, while striving for sustainable improvement in patient care.
This description is based on the current information on the official website and relevant scientific sources, as of 2025.
